Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2013 07:00 ET | Source: VIVUS, Inc.

VIVUS Announces Issuance of Two Key U.S. Patents for Qsymia; Patent Coverage for Qsymia Extended to 2029

MOUNTAIN VIEW, Calif., Nov. 13, 2013 (GLOBE NEWSWIRE) -- VIVUS,Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV...
November 12, 2013 08:00 ET | Source: VIVUS, Inc.

VIVUS Announces Scientific Presentations

MOUNTAIN VIEW, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- VIVUS,Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV...
November 12, 2013 07:00 ET | Source: VIVUS, Inc.

VIVUS to Present at Upcoming Investor Conference

MOUNTAIN VIEW, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that management will present an overview of the company at the following investment...
November 05, 2013 16:00 ET | Source: VIVUS, Inc.

VIVUS Reports Third Quarter and First Nine Months 2013 Financial Results

MOUNTAIN VIEW, Calif., Nov. 5, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV...
November 01, 2013 16:00 ET | Source: VIVUS, Inc.

VIVUS Announces Date of Third Quarter 2013 Financial Results and Conference Call

MOUNTAIN VIEW, Calif., Nov. 1, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the third quarter ended September 30, 2013 after the NASDAQ...
October 31, 2013 07:00 ET | Source: VIVUS, Inc.

Newly Published Study Finds Qsymia Achieves Greater Weight Loss at Lower Doses Than Either of Its Components as Monotherapy

MOUNTAIN VIEW, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) announced today that a newly-published study demonstrated Qsymia® (phentermine and topiramate extended-release)...
October 11, 2013 07:00 ET | Source: VIVUS, Inc.

VIVUS, Inc. Announces License Agreement for the Marketing Rights to STENDRA in the United States and Canada

MOUNTAIN VIEW, Calif., Oct. 11, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced the signing of an agreement providing Auxilium Pharmaceuticals, Inc. (Nasdaq:AUXL) the exclusive...
October 08, 2013 18:00 ET | Source: VIVUS, Inc.

Qsymia Shown to Reduce Progression to Type 2 Diabetes in High-Risk Overweight or Obese Patients

MOUNTAIN VIEW, Calif., Oct. 8, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced new data published online in Diabetes Care demonstrating the effects of Qsymia® (phentermine and...
September 27, 2013 17:15 ET | Source: VIVUS, Inc.

Peter Y. Tam Resigns as VIVUS President

MOUNTAIN VIEW, Calif., Sept. 27, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) the "Company") today announced that Peter Y. Tam will resign as president effective October 12, 2013. During his...
September 20, 2013 07:00 ET | Source: VIVUS, Inc.

VIVUS Updates European Filing Strategy for Qsiva

MOUNTAIN VIEW, Calif., Sept. 20, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced it has submitted to the European Medicines Agency (EMA) a request for scientific advice regarding...